22nd Dec 2005 10:05
GlaxoSmithKline PLC22 December 2005 Issued - Thursday 22 December 2005, London, UK / London Stock Exchangeannouncement GlaxoSmithKline plc Announces Changes to the Board of Directors GlaxoSmithKline plc (GSK) announces that two new Non-Executive Directors are tojoin the Board of the Company with effect from 1st January 2006 and that Dr LucyShapiro will be retiring as a Non-Executive Director at the Company's AnnualGeneral Meeting on 17th May 2006. The two new Non-Executives are: Dr Ralph Horwitz, Dean, School of Medicine and Vice President of Medical Affairs at Case Western Reserve University, Cleveland, Ohio and Director of Case Research Institute. Mr Tom De Swaan, Currently, Chief Financial Officer and member of the Management Board of ABN AMRO. In commenting on the retirement of Dr Shapiro and the appointment of Dr Horwitz,Sir Christopher Gent, Chairman of GSK, said: "During the last nine years Lucy has provided the Board with invaluable adviceand support for which I and my Board colleagues are immensely grateful. I am delighted that Ralph has agreed to join the Board. In addition tofulfilling his usual responsibilities as a Non-Executive Director, he will spendtime within our research and development organisation and, with his experience,will provide valuable insights to scientific and clinical developments outsideGSK." On his appointment to GSK, Mr De Swaan will join the Audit Committee and willsucceed Dr Ronaldo Schmitz as its Chairman in September 2006. Commenting on MrDe Swaan's appointment, Sir Christopher Gent said: "I am very glad that Tom, who has had a long and distinguished career ininternational banking, has agreed to join the Board and take over from Ronaldoas Chairman of the Audit Committee. This is a challenging and demanding rolethat Ronaldo has undertaken with great skill and I am delighted that he has alsoagreed to remain on the Board for a further term of three years." Biographical details of the Directors mentioned above are given below togetherwith a table showing the membership of the Board and its committees with effectfrom 1st January 2006. Simon Bicknell Company Secretary 22 December 2005 Notes 1. The Board has determined that Dr Horwitz and Mr De Swaan are eachindependent in accordance with the Combined Code on Corporate Governance. TheBoard also agreed that Dr Schmitz remains independent in character and judgementand that it would be appropriate for him to continue to be considered anindependent Non-Executive Director following the AGM in 2006, when he will havecompleted nine years service as a Non-Executive Director. 2. In accordance with the Combined Code, the Board has determined thatMr De Swaan has recent and relevant financial experience. The Board has alsoagreed that Mr De Swaan has the appropriate qualifications and background to bean Audit Committee Financial Expert in accordance with the requirements ofSarbanes-Oxley Act 2002. Biographical Details Dr Ralph Horwitz Age 58. Dr Horwitz was appointed vice president for medical affairs and dean ofthe School of Medicine at Case Western Reserve University and director of theCase Research Institute on April 1, 2003. Prior to joining Case, Ralph Horwitz was Harold H. Hines Professor of Medicineand Epidemiology at the Yale University School of Medicine and chairman of theDepartment of Internal Medicine, co-director of the Robert Wood Johnson ClinicalScholars Program, and chief of the Beeson Medical Service at Yale-New HavenHospital. Dr. Horwitz is internationally known for his pioneering research thathelped to establish the field of clinical investigation and outcomes research;for his distinguished leadership in reinvigorating the Department of Medicine atYale and for his innovative programs in the education of physicians and thetraining of physician scientists. Among his recent honours, he is the recipient of the Pennsylvania StateUniversity Distinguished Alumnus Award (2005) and the Robert J. Glaser ResearchAward (2005). He is an elected member of the American Society of ClinicalInvestigation, American Epidemiology Society, the Institute of Medicine of theNational Academy of Sciences, and the Association of American Physicians (AAP).He is a former chair of the American Board of Internal Medicine and is currentlya member of the Council of the AAP. Mr Tom De Swaan Age 59. Mr. De Swaan holds a Master degree in Economics and is a Member of theManaging Board and CFO of ABN AMRO. He will step down as CFO on 1 January 2006and retire from the Board of ABN AMRO from 1 May 2006. Prior to his tenure with ABN AMRO he was from 1986 - 1998 a Member of theGoverning Board of the Dutch Central Bank and in that capacity Chairman of theBasel Committee on Banking Supervision. He is a Non-Executive Director of the Financial Services Authority. He is aMember of the Board of the Institute of International Finance. He is Chairman ofthe Board of the Nederlands Opera and a Member of the Board of RoyalConcertgebouw Orchestra. Dr Ronaldo Schmitz Age 67. Dr Schmitz is an independent Non-Executive Director of GlaxoSmithKlineplc. He was a Non-Executive Director of Glaxo Wellcome plc from 1st January1997 until the completion of the merger with SmithKline Beecham plc in December2000. He is a Non-Executive Director of Legal & General Group plc and a memberof the Board of Directors of Rohm and Haas Company and Cabot Corporation. Dr Lucy Shapiro Age 65. Dr Shapiro is a Non-Executive Director of GlaxoSmithKline plc. She wasformerly aNon-Executive Director of SmithKline Beecham plc. She is Ludwig Professor ofCancer Research in the Department of Developmental Biology and Director of theBeckman Center for Molecular and Genetic Medicine at the Stanford UniversitySchool of Medicine and a Non-Executive Director of Anacor Pharmaceuticals, Inc.She holds a PhD in molecular biology from Albert Einstein College of Medicine. Board and Committee Membership with effect from 1st January 2006. Sir Christopher Gent Chairman Sir Ian Prosser Senior Independent Non-Executive Director Dr J-P Garnier Chief Executive Officer Mr J S Heslop Chief Financial Officer Dr Tachi Yamada Executive Director, Chairman, Research & Development Mr H Lawrence Culp Independent Non-Executive Director Sir Crispin Davis Independent Non-Executive Director Dr Ralph Horwitz Independent Non-Executive Director Sir Deryck Maughan Independent Non-Executive Director Dr Ronaldo Schmitz Independent Non-Executive Director Dr Lucy Shapiro Non-Executive Director Mr Tom De Swaan Independent Non Executive Director Sir Robert Wilson Independent Non-Executive Director Board Committee Committee Chairman Members Audit Dr Ronaldo Schmitz* Sir Deryck Maughan Sir Ian Prosser Mr Tom De Swaan* Sir Robert Wilson Remuneration Sir Robert Wilson Mr H Lawrence Culp Sir Crispin Davis Dr Ronaldo Schmitz Nominations Sir Christopher Gent Sir Ian Prosser Dr Ronaldo Schmitz Corporate Responsibility Sir Christopher Gent Sir Ian Prosser Dr Lucy Shapiro * Mr De Swaan will succeed Dr Schmitz as Chairman of the Audit Committee inSeptember 2006. Enquiries: UK Media enquiries: Philip Thomson (020) 8047 5502 David Mawdsley (020) 8047 5502 Chris Hunter-Ward (020) 8047 5502 US Media enquiries: Nancy Pekarek (215) 751 7709 Mary Anne Rhyne (919) 483 2839 Patricia Seif (215) 751 7709 European Analyst/Investor enquiries: Duncan Learmouth (020) 8047 5540 Anita Kidgell (020) 8047 5542 Jen Hill (020) 8047 5543 US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002 Tom Curry (215) 751 5419 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Glaxosmithkline